CellCentric
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
$220MSeries D
Role not disclosedLoading investors…
Activity from announced rounds
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
Builds and operates small GEO satellites for commercial and government communications
Pitching Fidelity Management & Research Company? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room